GlassScriptPhysician profile
Michael L Madden
NPI 1417980533
$275.52
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.86 · 2020: $71.78 · 2021: $92.61 · 2022: $29.27.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $53.32 | 2020 | |
| Vanda Pharmaceuticals INC. | $42.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $29.28 | 2019-2021 | |
| Neurelis, INC. | $29.27 | 2022 | |
| Xeris Pharmaceuticals, INC. | $28.22 | 2021 | |
| Abbvie INC. | $25.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.83 | 2019 | |
| Allergan, INC. | $18.46 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.65 | 2019 | |
| Novo Nordisk INC | $11.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Madden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.